BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) +/- chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)
Kopetz, S., Grothey, A., Yaeger, R., Ciardiello, F., Desai, J., Kim, T. W., . . . Tabernero, J. (2022). BREAKWATER: … Read More
